DUXAP10 and posterior cortical atrophy: Mounting evidence indicates that DUXAP10 is abnormally highly expressed in a variety of cancers, including HCC, lung cancer, glioma, RCC, PTC, PCa, CML, OC, GC, PC, BC, CRC, and ESCC.